/ About this event
For founders building AI-native healthcare & life science companies and the investors backing them.
As AI becomes core infrastructure in healthcare & life sciences, data rights, provenance, architecture, and governance are becoming part of fundraising and enterprise diligence. This session brings together founders, investors, healthtech operators and data governance leaders to examine the questions that increasingly determine whether an AI company is truly built to scale: where patient data comes from, how it is traced from ingestion to model output, what touches training pipelines, and who's accountable when something breaks.
Founders leave with a blueprint for building traceability and transparency into their architecture from day one whether they are MedTech, BioTools or Digital Health. Investors leave with a sharper diligence checklist for evaluating AI-native health companies before writing the check.
Discussion topics: - Data provenance: tracing a single data point from source document to model output - Training boundaries: how PHI is (or isn't) isolated from model fine-tuning - Consent & transparency: what an audit trail needs to look like to survive a HIPAA/BAA review - Vendor & EMR dependency risk: how much of a company's "traceability" story depends on a third party it doesn't control - Red flags vs. green flags: what separates real architectural transparency from a compliance slide bolted onto a pitch deck
Introduction & Event Kick-Off: Lauren M. Taylor, Partner at NDVC
Moderated by: Jen Gibson, Co-Founder & CEO, Xela OS
Panelists:
RJ Burnham, Founder and CEO, Consig Consig solves the problem of getting patients on the phone: post-discharge follow-up, intake forms, chronic care check-ins, appointment rebooking. Underneath it sits the part nobody demos: connect rates, and the compliance rules that change state by state. Then a clean handoff to staff or an AI agent. Previously CTO of Voxeo (acquired by Aspect), where he built the platform spun out as Tropo (acquired by Cisco), CEO of Sighthound, and President/CTO of Plum Voice.
Arvita Tripati is the Founder of Vahana Labs AI and a healthcare technology executive with nearly two decades of experience and 30+ regulated product launches across digital health, diagnostics, biopharma, and clinical technology. She advises founders, investors, and healthcare organizations on AI strategy, commercialization, governance, and enterprise readiness.
Rick Sanchez is the Chief AI Officer at Xela and an attorney who has led IP and AI governance strategy for organizations building on emerging technology, backed by AI credentials from MIT, Duke, and UT Austin and a background as a Navy Cryptologic Officer and electrical engineer. A recognized voice in the field, he serves on the State Bar of Texas Emerging Technology Committee and co-teaches AI Governance and Policy at Texas A&M School of Law, alongside speaking engagements at leading AI governance events.
Roger Kuan is a Partner at Norton Rose Fulbright and US Head of the Digital Health and Precision Medicine IP Practice, where he counsels companies that are uniquely positioned in the convergence of the life/medical sciences and technology industries on how to successfully navigate the complexities of the IP, data rights and regulatory challenges they encounter.
This event is a part of #SFTechWeek—a week of events hosted by VCs and startups to bring together the tech ecosystem. Learn more at www.tech-week.com.
